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Abstract 
Background: Secondary bladder amyloidosis is an extremely rare disease, resulting from a chronic systematic inflam-
matory disorder associated with amyloid deposits. Although uncommon in Japan, familial Mediterranean fever (FMF) 
is a hereditary autoinflammatory disease characterized by recurrent episodes of fever of short duration and serositis 
and is frequently associated with systemic amyloidosis. Here, we present a case of a Japanese patient complaining 
of fever and macroscopic hematuria after a living donor renal transplantation. Consequently, he was diagnosed with 
secondary bladder amyloidosis with FMF.
Case presentation: A 64-year-old Japanese male received a living ABO-incompatible kidney transplant from his wife. 
The postoperative clinical course was normal, and the patient was discharged 21 days after the transplantation with 
a serum creatinine level of 0.78 mg/dl. The patient frequently complained of general fatigue and fever of unknown 
origin. Six months later, the patient presented with continuous general fatigue, macroscopic hematuria, and fever. 
Cystoscopic examination of the bladder showed an edematous region with bleeding, and a transurethral biopsy 
revealed amyloid deposits. His wife stated that the patient had a recurrent high fever since the age of 40 years and 
that his younger brother was suspected to have a familial autoinflammatory syndrome; thus, the patient was also 
suspected to have a familial autoinflammatory syndrome. Based on his brother’s medical history and the genetic tests, 
which showed a homozygous mutation (M694V/M694V) for the Mediterranean fever protein, he was diagnosed with 
FMF. Although colchicine treatment for FMF was planned, the patient had an untimely death due to heart failure. We 
re-evaluated the pathological findings of the various tissue biopsies obtained during the treatment after the renal 
transplantation. Immunohistochemistry revealed amyloid deposits in the bladder region, renal allograft, and myocar-
dium and the condition was diagnosed as AA amyloidosis associated with FMF.
Conclusion: We presented a case of systemic amyloidosis with FMF, involving the bladder region, myocardium, and 
renal allograft, diagnosed after renal transplantation. Bladder amyloidosis should be considered in patients with mac-
roscopic hematuria, particularly in the kidney transplant recipients with idiopathic chronic renal disease. Diagnosis 
of secondary bladder amyloidosis may result in the early detection of underlying diseases, which may contribute to 
patient prognosis.
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Background
The amyloidoses contribute a large group of diseases 
associated with misfolding of extracellular protein [1]. 
Bladder involvement in amyloidosis is rare; and the 
involvement is mostly restricted to the bladder, which 
is called primary bladder amyloidosis [2]. Secondary 
bladder amyloidosis has been reported in patients with 
rheumatoid arthritis, Crohn’s disease, ankylosing spondy-
litis, multiple myeloma, and familial Mediterranean fever 
(FMF) [2]. FMF is a hereditary autoinflammatory dis-
ease characterized by recurrent episodes of fever of short 
duration and serositis, and it is frequently associated with 
systemic amyloidosis [3]. According to a nationwide sur-
vey, it is an uncommon disease that affects approximately 
300 patients in Japan [4].
Here, we report a rare case of secondary bladder amy-
loidosis as a part of systemic amyloidosis associated with 
FMF in a Japanese patient who underwent a living donor 
renal transplantation.
Case presentation
A 64-year-old pure Japanese male with end-stage idi-
opathic chronic kidney disease, scheduled to receive a 
living ABO-incompatible renal transplant from his wife, 
was referred to our renal transplant center in April 2012. 
His past medical history included angina pectoris and 
cholecystitis. Physical and laboratory findings were nor-
mal, except for the abnormal findings related to end-stage 
renal disease. The protocol for antibody removal before 
the transplant consisted of double-filtration plasmapher-
esis and rituximab. The induction immunosuppressive 
regimen included a combination of prolonged-release 
tacrolimus, mycophenolate mofetil, methylprednisolone, 
and basiliximab. Renal transplantation was performed 
in December 2012. The postoperative clinical course 
was normal, and the patient was discharged 21  days 
after the renal transplantation, with a serum creatinine 
level of 0.78  mg/dl. Three months after the renal trans-
plantation, the patient was admitted to our hospital with 
fever and general fatigue. Clinical examination, includ-
ing chest and abdominal computed tomography, blood 
and urine culture, and cardiac ultrasound, revealed no 
abnormal findings, and the symptoms improved after 
antibiotic treatment. Three months later, the patient 
complained of fever and macroscopic hematuria. Cys-
toscopic examination revealed edema and bleeding in 
the left anterior region of the bladder (Fig. 1a). Because 
cold biopsy of the abnormal mucosa showed no malig-
nant cells on hematoxylin–eosin staining (Fig.  1b), at 
that time, the bladder abnormality was suspected to be 
caused by viral hemorrhagic cystitis. The macroscopic 
hematuria stopped 3  days after dose reduction of the 
immunosuppressive drugs. Subsequently, the patient 
presented with intermittent fever, which resolved spon-
taneously within a few days. In May 2014, he presented 
with fever, general fatigue, and urinary retention and was 
re-admitted to our hospital. Ten days after admission, he 
required an artificial respirator and was transferred to 
an intensive care unit in circulatory shock. Because the 
precise cause for the aggravation of his general condition, 
frequent episodes of fever, and continuation of general 
fatigue was not clarified, his wife offered more details 
about the patient’s medical history. She stated that he had 
recurrent high fever since the age of 40 years and that his 
younger brother was suspected to have a familial autoin-
flammatory syndrome. After written informed consent, 
the patient’s serum sample was sent to the Department 
of Pediatrics at the Kyoto University Graduate School of 
Medicine for screening mutations and polymorphisms 
associated with hereditary autoinflammatory diseases. 
The ethics committee of the Akita University School of 
Medicine approved the use of human samples in the pre-
sent study. During waiting the results of the genetic test, 
the patient continued rehabilitation at a related hospital. 
However, 2 months after discharge from our hospital, he 
presented with fever and heart failure and was re-admit-
ted. At that time, he was found to be homozygous for the 
Mediterranean fever (MEFV) mutation (M694V/M694V) 
(Fig.  2). Based on the presence of the MEFV mutation 
and the patient’s history, he was diagnosed with FMF. 
Treatment with colchicine was planned, but the patient 
died from heart failure in October 2014. We re-evaluated 
the pathological findings of the various tissue biopsies 
obtained during his treatment after the renal transplan-
tation because FMF is known to be associated with sys-
temic amyloidosis. Immunohistochemistry revealed 
amyloid deposits in the abnormal bladder region (Fig. 1c, 
d), transplanted kidney, and myocardium, which was 
diagnosed as AA amyloidosis associated with FMF.
Discussion
Hematuria has a prevalence of 12  % in the post renal 
transplant patients with the major causes such as urinary 
tract infection, genitourinary malignancies, graft rejec-
tion, recurrences of primary disease and calculus [5]. 
Although bladder amyloidosis mainly presented intermit-
tent painless macroscopic hematuria [6], we had not con-
sidered bladder amyloidosis at the time of the presence of 
macroscopic hematuria because of its rare cause of mac-
roscopic hematuria in post renal transplant patients.
Amyloidosis is mainly classified into primary (AL) or 
secondary (AA), according to the biochemical nature of 
the protein forming the fibril [2]. The secondary bladder 
amyloidosis incidence is lower than primary localized 
bladder amyloidosis [7]. Secondary bladder amyloidosis 
is often associated with a chronic inflammatory disease; 
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only 30 cases have been previously reported [2]. One 
patient presented with secondary bladder amyloidosis 
with FMF in a large study of systemic amyloidosis and 
FMF [8]. To our knowledge, this is the second case of 
secondary amyloidosis associated with FMF and the first 
case of secondary bladder amyloidosis in an FMF patient 
treated with renal transplantation. Although a rare cause 
of macroscopic hematuria in renal transplant patients, 
the presence of secondary bladder amyloidosis associated 
with a systemic disease should be considered, particularly 
in renal transplant recipients with idiopathic chronic kid-
ney disease.
Fig. 1 a Cystoscopic examination revealed edema and bleeding in the left anterior region of the bladder. b Hematoxylin–eosin staining of the 
amorphous structure showed no malignant cells and diffuse homogenous deposits. c Immunostaining for AA amyloidosis was positive in bladder 
biopsy. d Congo red staining under polarized light was positive in bladder biopsy
Fig. 2 DNA sequence electropherograms demonstrating the M694V mutation of the Mediterranean fever (MEFV) gene
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FMF is a disease associated with a mutation in the 
MEFV gene, which is located on chromosome 16 and 
encodes a 781-amino-acid protein named pyrin [9]. 
This protein may play a pivotal role in inflammation and 
apoptosis regulation [3]. In a study on renal transplan-
tation in FMF patients [10], during a mean follow-up 
of 35  months, all allografts were functioning well and 
the patients’ mean serum creatinine level was 1.4  mg/
dl. Because the outcome after renal transplantation is 
mainly influenced by cardiac disease severity [11], the 
Canadian Society of Transplantation recommends renal 
transplantation for patients with amyloidosis if there is 
no evidence of cardiac involvement [11]. Before renal 
transplantation, we could not detect any cardiac problem 
on the electrocardiogram, chest radiograph, or cardiac 
ultrasound, except for a mild tricuspid valve insufficiency. 
We should be careful about abnormal findings related to 
systemic amyloidosis in patients with renal transplanta-
tion during routine screenings and post-transplantation 
follow up. Furthermore, if a kidney biopsy had been per-
formed to elucidate the cause of the idiopathic chronic 
kidney disease, amyloidosis may have been diagnosed at 
an earlier stage. It is also important to identify the cause 
of idiopathic chronic kidney disease before renal trans-
plantation, particularly in patients with symptoms of 
unknown origin and familial history.
The main treatment strategy for secondary amyloido-
sis is control of underlying disease. As an antigout and 
antimitotic agent that decreases leukocyte motility and 
phagocytosis in inflammatory responses, continuous col-
chicine use is recommended to prevent frequent attacks 
and amyloidosis in FMF [12]. Colchicine administration 
may be helpful in preventing further complications and 
improving the prognosis in our patient.
Conclusion
We presented a case of FMF with systemic amyloidosis 
involving the bladder, myocardium, and renal allograft 
diagnosed after the renal transplantation. The patient 
died of heart failure because of cardiac amyloidosis with-
out receiving any treatment for FMF. Although bladder 
amyloidosis associated with FMF is rare, it should be 
considered in patients with gross hematuria, particu-
larly renal transplant recipients with idiopathic end-stage 
renal disease.
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